文献速递妇科

剂量密集型卡铂紫杉醇改善子宫内膜癌患者无进展生存期

Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2017-07-20

回顾性队列研究比较剂量密集方案(每周紫杉醇+每3周卡铂)与标准3周方案在高危和中高危子宫内膜癌辅助治疗中的价值,共纳入122例患者,剂量密集组61例,标准组61例。剂量密集组3年无进展生存率为79.5%,标准组为57.4%(P=0.03),多因素分析风险比为0.4(95%CI 0.2-0.8,P=0.01)。初步数据提示剂量密集化疗可能是合理的辅助治疗选择。

要点

  • 剂量密集组3年无进展生存率79.5%,标准组57.4%(P=0.03)。
  • 多因素分析风险比0.4(95%CI 0.2-0.8,P=0.01),剂量密集组进展事件更少。
  • 标准组肌肉骨骼疼痛更常见(27.9% vs 6.6%,P=0.005)。

核心结论

  • 初步数据提示,与标准化疗相比,剂量密集化疗可能是子宫内膜癌辅助治疗合理且更优的选择。

研究设计与样本

  • 回顾性队列研究,比较2011年至2015年接受剂量密集方案(每周紫杉醇+每3周卡铂)的高危和中高危子宫内膜癌连续患者与2008年至2011年接受标准3周方案的相似特征非重叠历史队列。
  • 共纳入122例子宫内膜癌患者,剂量密集组61例,标准3周组61例。

主要发现

  • 标准3周队列中位随访61.6个月,剂量密集队列中位随访41.6个月,共记录40例进展。
  • 标准方案组29例进展,3年无进展生存率为57.4%;剂量密集方案组11例进展,3年无进展生存率为79.5%(P=0.03)。
  • 多因素分析中,剂量密集方案组发生进展事件的风险比标准队列低,风险比为0.4(95%CI 0.2-0.8,P=0.01)。
  • 剂量密集方案组远处转移显著更少(P=0.01),晚期疾病诊断时总生存期改善(P=0.02)。
  • 肌肉骨骼疼痛主诉在标准队列更频繁(17例,27.9%),剂量密集队列为4例,6.6%(P=0.005)。

临床怎么用

  • 作者认为,剂量密集化疗可能是子宫内膜癌辅助治疗合理且更优的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pilot study to assess the value of weekly paclitaxel plus carboplatin every 3weeks (dose dense regimen, DD) compared to the standard 3-weekly protocol in the adjuvant setting for endometrial cancer. METHODS: Retrospective cohort study comparing consecutive patients with high and intermediate-high risk endometrial cancer, undergoing DD protocol (from 2011 to 2015) to a non-overlapping historical cohort with similar characteristics who received treatment every three weeks (2008-2011). RESULTS: 122 patients with endometrial cancer were included in the study, of these, 61 patients received the dose dense protocol and 61 were treated with the standard 3-weekly protocol. After a median follow-up of 61.6months in the 3-weekly cohort, compared with 41.6months in the DD cohort, 40 progressions were recorded. 29 progressions were observed in women treated in the standard protocol, with a three years progression free survival (PFS) of 57.4%, compared to 11 progressions observed in patients in the DD schedule, with a three years PFS of 79.5% (P=0.03). Patients who were treated with the DD protocol were less likely to have progression events compared to the standard cohort with a hazard ratio of 0.4 on multivariate analysis (CI 95%, 0.2-0.8, P=0.01), had significantly less distant metastases (P=0.01), and had improved overall survival when diagnosed with advanced stage disease (P=0.02). Complaints of musculoskeletal pain were more frequent in the standard cohort (n=17, 27.9%) compared to the dose dense cohort (n=4, 6.6%), P=0.005. CONCLUSION: Preliminary data suggests that dose dense chemotherapy might be a reasonable and superior option for adjuvant treatment of endometrial cancer, compared to standard chemotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kogan L, Laskov I, Amajoud Z, et al. Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. Gynecol Oncol. 2017. PMID: 28735629. doi:10.1016/j.ygyno.2017.07.134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。